Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF4A1 | P60842 | 18/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18864999 | 1.00 | EIF4A1 (0.53) | EIF4A1CYP3A4HIF1ANFKB1RELA | |
| SCHEMBL18865049 | 0.92 | EIF4A1 (0.51) | EIF4A1CYP3A4HIF1ANFKB1RELA | |
| SCHEMBL18865051 | 0.92 | EIF4A1 (0.51) | EIF4A1CYP3A4HIF1ANFKB1RELA | |
| SCHEMBL26312678 | 0.92 | EIF4A1 (0.63) | EIF4A1CYP3A4HIF1ANFKB1RELA | |
| SCHEMBL18877975 | 0.92 | EIF4A1 (0.63) | EIF4A1CYP3A4HIF1ANFKB1RELA | |
| SCHEMBL18864650 | 0.92 | EIF4A1 (0.53) | EIF4A1CYP3A4HIF1ANFKB1RELA | |
| SCHEMBL30688198 | 0.92 | EIF4A1 (0.53) | EIF4A1CYP3A4HIF1ANFKB1RELA | |
| SCHEMBL18864679 | 0.92 | EIF4A1 (0.53) | EIF4A1CYP3A4HIF1ANFKB1RELA | |
| SCHEMBL30688145 | 0.90 | EIF4A1 (0.52) | EIF4A1CYP3A4HIF1ANFKB1RELA | |
| SCHEMBL18865267 | 0.90 | EIF4A1 (0.52) | EIF4A1CYP3A4HIF1ANFKB1RELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3888658-B1 | EIF4-A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS INC (US) | 2023-12-27 | — | — | EP | disclosed |
| US-20230295179-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230071483-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2023-03-09 | — | — | US | disclosed |
| US-11440917-B2 | EIF4A-inhibiting compounds and methods related thereto | EFFECTOR THERAPEUTICS, INC. (US) | 2022-09-13 | — | — | US | disclosed |
| EP-3888658-A1 | EIF4-A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | Effector Therapeutics Inc. (US) | 2021-10-06 | — | — | EP | disclosed |
| EP-3380101-B1 | EIF4-A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS INC (US) | 2021-01-27 | — | — | EP | disclosed |
| US-20200339590-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | eFector Therapautics, Inc. (US) | 2020-10-29 | — | — | US | disclosed |
| US-10577378-B2 | EIF4A-inhibiting compounds and methods related thereto | EFFECTOR THERAPEUTICS, INC. (US) | 2020-03-03 | — | — | US | disclosed |
| US-20180298017-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. (US) | 2018-10-18 | — | — | US | disclosed |
| EP-3380101-A1 | EIF4-A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | Effector Therapeutics Inc. (US) | 2018-10-03 | — | — | EP | disclosed |
| US-9957277-B2 | eIF4A-inhibiting compounds and methods related thereto | EFFECTOR THERAPEUTICS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| WO-2017091585-A1 | EIF4-A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. (US) | 2017-06-01 | — | — | WO | disclosed |
| US-20170145026-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. | 2017-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339590-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EIF4A1, EIF4A2, EIF4A3 | EIF4A1 1/4885CYP3A4 3154/4885HIF1A 1343/4885 |
| US-20230295179-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EIF4A1, EIF4A2, EIF4A3 | EIF4A1 1/4885CYP3A4 3154/4885HIF1A 1343/4885 |
| US-20230071483-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EIF4A1, EIF4A2, EIF4A3 | EIF4A1 1/4885CYP3A4 3154/4885HIF1A 1343/4885 |
| US-11440917-B2 | EIF4A-inhibiting compounds and methods related thereto | EIF4A1, EIF4A2, EIF4A3 | EIF4A1 1/4885CYP3A4 3154/4885HIF1A 1343/4885 |
| US-20180298017-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EIF4A1, EIF4A2, EIF4A3 | EIF4A1 1/4885CYP3A4 3154/4885HIF1A 1343/4885 |
| US-10577378-B2 | EIF4A-inhibiting compounds and methods related thereto | EIF4A1, EIF4A2, EIF4A3 | EIF4A1 1/4885CYP3A4 3154/4885HIF1A 1343/4885 |
| US-20170145026-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EIF4A1, EIF4A2, EIF4A3 | EIF4A1 1/4885CYP3A4 3154/4885HIF1A 1343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.